MesoRNA

MesoRNA specializes in advanced sequencing technologies for small non-coding RNAs, known as mesoRNAs, which range from 30 to 300 nucleotides. The company has developed its proprietary MSR-seq technology to enable comprehensive, multiplexed next-generation sequencing (NGS) library preparation. This platform allows researchers to measure tens of thousands of unique molecules per sample with high base-calling accuracy. Additionally, the company provides a full-service laboratory option for sample processing and is developing a TL-qPCR assay intended to translate biomarker discoveries into diagnostic applications. By addressing the technical challenges historically associated with studying these pervasive but under-researched molecules, MesoRNA aims to complete the understanding of the central dogma of molecular biology.

These tools serve academic laboratories, core facilities, and diagnostic developers who require precise, scalable methods to analyze the biological roles of mesoRNAs. By streamlining the workflow from library preparation to bioinformatics analysis, the company helps users overcome previous limitations in small RNA research. MesoRNA, founded in 2023 and based in Chicago, grew out of over a decade of academic research led by Dr. Tao Pan. The company provides a crucial resource for institutions seeking to investigate the regulatory functions of non-coding RNAs, which constitute a significant majority of human cellular nucleic acids, potentially unlocking new pathways for biological discovery and diagnostic development.